Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index.

ABSTRACT:

Background

Immuno-oncology (IO) is rapidly evolving in early drug development. We aimed to develop and prospectively validate a prognostic index for patients treated in IO phase I trials to assist with patient selection.

Methods

The development cohort included 192 advanced solid tumor patients treated in 13 IO phase I trials, targeting immune checkpoint and/or co-stimulatory molecules. A prognostic scoring system was developed from multivariate survival analysis of 10 clinical factors, and subsequently validated in two independent validation cohorts (n = 152 and n = 80).

Results

In the development cohort, median age was 57.5 years (range = 20.4-84.8 years). Median progression-free survival and overall survival (OS) were 13.4 and 73.6 weeks, respectively, 90-day mortal

SUBMITTER: Day D 

PROVIDER: S-EPMC7050022 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature